AveXis, Inc. (AVXS) Scheduled to Post Earnings on Wednesday
AveXis, Inc. (NASDAQ:AVXS) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 9th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.13. During the same period in the previous year, the business earned ($1.24) EPS. On average, analysts expect AveXis to post $-4.33 EPS for the current fiscal year and $-4.05 EPS for the next fiscal year.
AveXis, Inc. (NASDAQ AVXS) opened at 96.35 on Monday. The firm has a 50-day moving average of $80.67 and a 200-day moving average of $71.89. AveXis, Inc. has a 12-month low of $31.55 and a 12-month high of $97.00. The firm’s market cap is $2.68 billion.
In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $70.91, for a total value of $126,219.80. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at $126,219.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 5,340 shares of company stock valued at $434,872 over the last 90 days. 18.60% of the stock is currently owned by corporate insiders.
WARNING: “AveXis, Inc. (AVXS) Scheduled to Post Earnings on Wednesday” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/07/avexis-inc-avxs-scheduled-to-post-earnings-on-wednesday.html.
AVXS has been the subject of a number of recent research reports. Jefferies Group LLC restated a “buy” rating and issued a $92.00 target price on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. initiated coverage on AveXis in a research note on Tuesday, May 23rd. They issued a “buy” rating and a $90.00 target price for the company. BMO Capital Markets restated an “outperform” rating and issued a $95.00 target price on shares of AveXis in a research note on Friday, June 16th. Chardan Capital set a $103.00 target price on AveXis and gave the company a “buy” rating in a research note on Sunday, June 18th. Finally, Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $93.60.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.